### Comparison: other vs 'Sorafenib'

**Treatment** | **HR** | **95%-CI**
--- | --- | ---
Atezolizumab+Bevacizumab | 0.43 | [0.25; 0.73]
Atezolizumab+Cabozantinib | 1.10 | [0.72; 1.68]
Camrelizumab+Apatinib | 0.45 | [0.18; 1.14]
Durvalumab | 1.05 | [0.75; 1.47]
Durvalumab+Tremelimunab | 1.06 | [0.76; 1.48]
Lenvatinib | 0.91 | [0.66; 1.26]
Nivolumab | 0.71 | [0.49; 1.02]
Pembrolizumab+Lenvatinib | 0.78 | [0.48; 1.27]
Placebo | 2.00 | [1.29; 3.10]
Tislelizumab | 0.64 | [0.38; 1.08]

**Supplementary Figure 23.** Forest plots showing the overall survival in subpopulation with HCV-related HCC considering sorafenib as reference.